Senores Pharmaceuticals Limited IPO

BSE, NSEClosed

Check Allotment

Dec 20, 2024Open Date

Dec 24, 2024Close Date

TBAAllotment Date

Dec 30, 2024Listing Date

Subscription Details

View Subscription Details

Retail89.23x

QIB94.66x

NIIs (Non-Institutional Investors)Main Category

96.11x

↳ NII Sub-Categories

bHNI (> ₹10L)

Bids above ₹10L

93.53x

sHNI (< ₹10L)

Bids ₹2L to ₹10L

101.27x

Overall Subscription

Total Bids Received

93.41x

Updated: 10 Jul, 06:09 pm

Senores Pharmaceuticals Limited IPO Issue Details

Issue Price₹372-391 Per Equity Share

Face Value₹10 Per Equity Share

Fresh Share1,27,87,723 shares(aggregating up to ₹500 crore)

Listing AtBSE, NSE

Listing DateDec 30, 2024

RegistrarLink Intime India Private Ltd

Market Lot Details

Category	Lots	Shares	Amount
sHNI (Min)	14	532	₹2,08,012
sHNI (Max)	67	2,546	₹9,95,486
bHNI (Min)	68	2,584	₹10,10,344

Reservation Details

Category	Shares Offered	%
NII	22,21,909	15%
QIB	44,43,817	30%
Anchor	66,65,725	45%

Valuations

EPS (Pre-IPO)

9.83

EPS (Post-IPO)

13.86

P/E (Pre-IPO)

39.77

P/E (Post-IPO)

28.21

RoNW

23.60%

PAT Margin

15.25%

P/B Value

5.84

Financial Information (₹ in Crores)

Metric	FY 24	FY 23	FY 22
Total Assets	621.88	131.05	59.15
Total Revenue	217.34	39.02	14.63
Profit After Tax	32.71	8.43	0.99
Net Worth	231.71	45.5	36.59

* All figures are in ₹ Crores unless otherwise stated.

Objectives of the Issue

1Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(Havix), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility
2Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
3Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary
4Funding the working capital requirements of the Company;
5Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (SPI)and Ratnatris Pharmaceutical Private Limited (Ratnatris), to fund their working capital requirements.
6Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.